Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Immunocore Holdings plc or Corcept Therapeutics Incorporated because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Immunocore Holdings plc and Corcept Therapeutics Incorporated compare based on key financial metrics to determine which better meets your investment needs.

About Immunocore Holdings plc and Corcept Therapeutics Incorporated

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig’s disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Latest Biotechnology and Immunocore Holdings plc, Corcept Therapeutics Incorporated Stock News

As of July 31, 2026, Immunocore Holdings plc had a $1.7 billion market capitalization, compared to the Biotechnology median of $252.6 million. Immunocore Holdings plc’s stock is down 2.6% in 2026, down 3.4% in the previous five trading days and up 0.93% in the past year.

Currently, Immunocore Holdings plc does not have a price-earnings ratio. Immunocore Holdings plc’s trailing 12-month revenue is $412.8 million with a -6.7% net profit margin. Year-over-year quarterly sales growth most recently was 13.6%. Analysts expect adjusted earnings to reach $0.134 per share for the current fiscal year. Immunocore Holdings plc does not currently pay a dividend.

As of July 31, 2026, Corcept Therapeutics Incorporated had a $12.4 billion market cap, putting it in the 80th percentile of all stocks. Corcept Therapeutics Incorporated’s stock is up 229% in 2026, up 20.1% in the previous five trading days and up 63.77% in the past year.

Currently, Corcept Therapeutics Incorporated’s price-earnings ratio is 252.2. Corcept Therapeutics Incorporated’s trailing 12-month revenue is $830.8 million with a 6.6% net profit margin. Year-over-year quarterly sales growth most recently was 31.7%. Analysts expect adjusted earnings to reach $2.280 per share for the current fiscal year. Corcept Therapeutics Incorporated does not currently pay a dividend.

How We Compare Immunocore Holdings plc and Corcept Therapeutics Incorporated Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Immunocore Holdings plc and Corcept Therapeutics Incorporated’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Immunocore Holdings plc and Corcept Therapeutics Incorporated Stock Value Grades

Company	Ticker	Value
Immunocore Holdings plc	IMCR	F
Corcept Therapeutics Incorporated	CORT	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Immunocore Holdings plc has a Value Score of 19, which is Ultra Expensive. Corcept Therapeutics Incorporated has a Value Score of 3, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Immunocore Holdings plc or Corcept Therapeutics Incorporated has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Immunocore Holdings plc or Corcept Therapeutics Incorporated is the better investment when it comes to value.

Immunocore Holdings plc and Corcept Therapeutics Incorporated’s Quality Grades

Company	Ticker	Quality
Immunocore Holdings plc	IMCR	D
Corcept Therapeutics Incorporated	CORT	B

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Immunocore Holdings plc has a Quality Score of 29, which is Weak. Corcept Therapeutics Incorporated has a Quality Score of 78, which is Strong.

The Quality Grade Winner: Corcept Therapeutics Incorporated

As you can clearly see from the Quality Grade breakdown above, Corcept Therapeutics Incorporated has a better overall quality grade than Immunocore Holdings plc. For investors who are looking for companies with higher quality than others in the same industry, Corcept Therapeutics Incorporated could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Immunocore Holdings plc and Corcept Therapeutics Incorporated’s Momentum Grades

Company	Ticker	Momentum
Immunocore Holdings plc	IMCR	C
Corcept Therapeutics Incorporated	CORT	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Immunocore Holdings plc has a Momentum Score of 57, which is Average. Corcept Therapeutics Incorporated has a Momentum Score of 98, which is Very Strong.

The Momentum Grade Winner: Corcept Therapeutics Incorporated

As you can clearly see from the Momentum Grade breakdown above, Corcept Therapeutics Incorporated is considered to have stronger momentum compared to Immunocore Holdings plc. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Corcept Therapeutics Incorporated could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Immunocore Holdings plc and Corcept Therapeutics Incorporated Grades

In addition to Momentum, Value and Quality, A+ Investor also provides grades for Growth and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Immunocore Holdings plc and Corcept Therapeutics Incorporated pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Immunocore Holdings plc or Corcept Therapeutics Incorporated Stock?

Overall, Immunocore Holdings plc stock has a Value Score of 19, Momentum Score of 57 and Quality Score of 29.

Corcept Therapeutics Incorporated stock has a Value Score of 3, Momentum Score of 98 and Quality Score of 78.

Comparing Immunocore Holdings plc and Corcept Therapeutics Incorporated’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.